Literature DB >> 10684303

Identification and analysis of the K5 gene of Kaposi's sarcoma-associated herpesvirus.

M Haque1, J Chen, K Ueda, Y Mori, K Nakano, Y Hirata, S Kanamori, Y Uchiyama, R Inagi, T Okuno, K Yamanishi.   

Abstract

Kaposi's sarcoma-associated herpesvirus (KSHV), or human herpesvirus 8 (HHV-8), belongs to the gammaherpesvirus subfamily and encodes approximately 80 open reading frames (ORFs). Among them are a few candidates for immediate-early genes (e.g., K5). We developed a monoclonal antibody (MAb), 328C7, against the K5 antigen. This MAb reacted with the K5 gene product by immunoscreening of a cDNA library from BCBL-1 cells, and this result was confirmed by transfection of the K5 ORF into Cos-7 cells. After induction of lytic infection by treatment with 12-O-tetradecanoylphorbol-13-acetate, MAb 328C7 reacted with an antigen in the cytoplasm of BCBL-1 and BC-3 cells as early as after 4 h of induction. Immunoelectron microscopy showed that the K5 antigen was situated mainly in the endoplasmic reticulum but was not present on the virion or in the nucleus. Northern blotting with a K5-specific probe revealed a single transcript of 1.2 kb, while Western blotting showed the antigen to be a 36-kDa polypeptide. The 5' and 3' ends were then determined by rapid amplification of cDNA, followed by sequencing of RACE products, and a splice was revealed upstream of the K5 ORF. K5 expression was unaffected by the respective DNA and protein synthesis inhibitors phosphonoformic acid and cycloheximide plus actinomycin D, confirming its immediate-early nature. Transient-transfection assays showed that the K5 promoter was transactivated by ORF 50 (KSHV Rta), a homolog of Epstein-Barr virus Rta, but the K5 gene product exhibited no transregulation of its own promoter or those of DNA polymerase and the human immunodeficiency virus type 1 long terminal repeat. This is the first such analysis of an immediate-early gene product; determination of its specific biological function requires further investigation.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10684303      PMCID: PMC111777          DOI: 10.1128/jvi.74.6.2867-2875.2000

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  47 in total

1.  Identification of the immediate-early transcripts of Kaposi's sarcoma-associated herpesvirus.

Authors:  F X Zhu; T Cusano; Y Yuan
Journal:  J Virol       Date:  1999-07       Impact factor: 5.103

2.  Kaposi's sarcoma-associated herpesvirus (KSHV or HHV8) in primary effusion lymphoma: ultrastructural demonstration of herpesvirus in lymphoma cells.

Authors:  W Said; K Chien; S Takeuchi; T Tasaka; H Asou; S K Cho; S de Vos; E Cesarman; D M Knowles; H P Koeffler
Journal:  Blood       Date:  1996-06-15       Impact factor: 22.113

3.  Viral FLICE-inhibitory proteins (FLIPs) prevent apoptosis induced by death receptors.

Authors:  M Thome; P Schneider; K Hofmann; H Fickenscher; E Meinl; F Neipel; C Mattmann; K Burns; J L Bodmer; M Schröter; C Scaffidi; P H Krammer; M E Peter; J Tschopp
Journal:  Nature       Date:  1997-04-03       Impact factor: 49.962

4.  MatInd and MatInspector: new fast and versatile tools for detection of consensus matches in nucleotide sequence data.

Authors:  K Quandt; K Frech; H Karas; E Wingender; T Werner
Journal:  Nucleic Acids Res       Date:  1995-12-11       Impact factor: 16.971

5.  Interaction of bovine herpesvirus 4 (BHV-4) immediate early 2 gene product with BHV-4 thymidine kinase promoter-regulatory region.

Authors:  L Zhang; V L van Santen
Journal:  J Gen Virol       Date:  1995-10       Impact factor: 3.891

6.  Primary characterization of a herpesvirus agent associated with Kaposi's sarcomae.

Authors:  P S Moore; S J Gao; G Dominguez; E Cesarman; O Lungu; D M Knowles; R Garber; P E Pellett; D J McGeoch; Y Chang
Journal:  J Virol       Date:  1996-01       Impact factor: 5.103

7.  Establishment of AIDS-related lymphoma cell lines from lymphomatous effusions.

Authors:  G Gaidano; K Cechova; Y Chang; P S Moore; D M Knowles; R Dalla-Favera
Journal:  Leukemia       Date:  1996-07       Impact factor: 11.528

8.  A role for a new herpes virus (KSHV) in different forms of Kaposi's sarcoma.

Authors:  M Schalling; M Ekman; E E Kaaya; A Linde; P Biberfeld
Journal:  Nat Med       Date:  1995-07       Impact factor: 53.440

9.  Antibodies to butyrate-inducible antigens of Kaposi's sarcoma-associated herpesvirus in patients with HIV-1 infection.

Authors:  G Miller; M O Rigsby; L Heston; E Grogan; R Sun; C Metroka; J A Levy; S J Gao; Y Chang; P Moore
Journal:  N Engl J Med       Date:  1996-05-16       Impact factor: 91.245

10.  Lytic growth of Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) in culture.

Authors:  R Renne; W Zhong; B Herndier; M McGrath; N Abbey; D Kedes; D Ganem
Journal:  Nat Med       Date:  1996-03       Impact factor: 53.440

View more
  39 in total

1.  Activation of latent Kaposi's sarcoma-associated herpesvirus by demethylation of the promoter of the lytic transactivator.

Authors:  J Chen; K Ueda; S Sakakibara; T Okuno; C Parravicini; M Corbellino; K Yamanishi
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-27       Impact factor: 11.205

Review 2.  Split genes and their expression in Kaposi's sarcoma-associated herpesvirus.

Authors:  Zhi-Ming Zheng
Journal:  Rev Med Virol       Date:  2003 May-Jun       Impact factor: 6.989

Review 3.  Molecular biology of KSHV in relation to AIDS-associated oncogenesis.

Authors:  Whitney Greene; Kurt Kuhne; Fengchun Ye; Jiguo Chen; Fuchun Zhou; Xiufen Lei; Shou-Jiang Gao
Journal:  Cancer Treat Res       Date:  2007

4.  Genetic organization and hypoxic activation of the Kaposi's sarcoma-associated herpesvirus ORF34-37 gene cluster.

Authors:  Muzammel Haque; Victoria Wang; David A Davis; Zhi-Ming Zheng; Robert Yarchoan
Journal:  J Virol       Date:  2006-07       Impact factor: 5.103

5.  Kaposi sarcoma herpesvirus K5 removes CD31/PECAM from endothelial cells.

Authors:  Mandana Mansouri; Janet Douglas; Patrick P Rose; Kristine Gouveia; Gary Thomas; Robert E Means; Ashlee V Moses; Klaus Früh
Journal:  Blood       Date:  2006-04-06       Impact factor: 22.113

6.  Transcription pattern of human herpesvirus 8 open reading frame K3 in primary effusion lymphoma and Kaposi's sarcoma.

Authors:  P Rimessi; A Bonaccorsi; M Stürzl; M Fabris; E Brocca-Cofano; A Caputo; G Melucci-Vigo; M Falchi; A Cafaro; E Cassai; B Ensoli; P Monini
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

7.  Major Histocompatibility Complex Class II HLA-DRα Is Downregulated by Kaposi's Sarcoma-Associated Herpesvirus-Encoded Lytic Transactivator RTA and MARCH8.

Authors:  Zhiguo Sun; Hem Chandra Jha; Yong-Gang Pei; Erle S Robertson
Journal:  J Virol       Date:  2016-08-26       Impact factor: 5.103

Review 8.  Molecular biology of Kaposi's sarcoma-associated herpesvirus and related oncogenesis.

Authors:  Qiliang Cai; Suhbash C Verma; Jie Lu; Erle S Robertson
Journal:  Adv Virus Res       Date:  2010       Impact factor: 9.937

9.  Binding of RBP-Jkappa (CSL) protein to the promoter of the Kaposi's sarcoma-associated herpesvirus ORF47 (gL) gene is a critical but not sufficient determinant of transactivation by ORF50 protein.

Authors:  Pey-Jium Chang; Joseph Boonsiri; Shih-Shan Wang; Li-Yu Chen; George Miller
Journal:  Virology       Date:  2009-12-16       Impact factor: 3.616

10.  Genome-wide identification of binding sites for Kaposi's sarcoma-associated herpesvirus lytic switch protein, RTA.

Authors:  Jiguo Chen; Fengchun Ye; Jianping Xie; Kurt Kuhne; Shou-Jiang Gao
Journal:  Virology       Date:  2009-02-23       Impact factor: 3.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.